ESPR
Price
$1.17
Change
+$0.02 (+1.74%)
Updated
Jul 3 closing price
Capitalization
495.94M
31 days until earnings call
ORGO
Price
$4.25
Change
+$0.20 (+4.94%)
Updated
Jul 3 closing price
Capitalization
374.78M
32 days until earnings call
Interact to see
Advertisement

ESPR vs ORGO

Header iconESPR vs ORGO Comparison
Open Charts ESPR vs ORGOBanner chart's image
Esperion Therapeutics
Price$1.17
Change+$0.02 (+1.74%)
Volume$2.32M
Capitalization495.94M
Organogenesis Holdings
Price$4.25
Change+$0.20 (+4.94%)
Volume$494.56K
Capitalization374.78M
ESPR vs ORGO Comparison Chart in %
Loading...
ESPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORGO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ESPR vs. ORGO commentary
Jul 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ESPR is a StrongBuy and ORGO is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 05, 2025
Stock price -- (ESPR: $1.17 vs. ORGO: $4.25)
Brand notoriety: ESPR and ORGO are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: ESPR: 51% vs. ORGO: 37%
Market capitalization -- ESPR: $495.94M vs. ORGO: $374.78M
ESPR [@Pharmaceuticals: Other] is valued at $495.94M. ORGO’s [@Pharmaceuticals: Other] market capitalization is $374.78M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.8B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ESPR’s FA Score shows that 0 FA rating(s) are green whileORGO’s FA Score has 1 green FA rating(s).

  • ESPR’s FA Score: 0 green, 5 red.
  • ORGO’s FA Score: 1 green, 4 red.
According to our system of comparison, ORGO is a better buy in the long-term than ESPR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ESPR’s TA Score shows that 6 TA indicator(s) are bullish while ORGO’s TA Score has 6 bullish TA indicator(s).

  • ESPR’s TA Score: 6 bullish, 4 bearish.
  • ORGO’s TA Score: 6 bullish, 5 bearish.
According to our system of comparison, ESPR is a better buy in the short-term than ORGO.

Price Growth

ESPR (@Pharmaceuticals: Other) experienced а +14.71% price change this week, while ORGO (@Pharmaceuticals: Other) price change was +17.73% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +2.13%. For the same industry, the average monthly price growth was +3.08%, and the average quarterly price growth was +93.03%.

Reported Earning Dates

ESPR is expected to report earnings on Aug 05, 2025.

ORGO is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+2.13% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ESPR($496M) has a higher market cap than ORGO($375M). ORGO YTD gains are higher at: 32.812 vs. ESPR (-46.818). ORGO has higher annual earnings (EBITDA): 36M vs. ESPR (-150.11M). ORGO has more cash in the bank: 104M vs. ESPR (82.2M). ORGO has less debt than ESPR: ORGO (119M) vs ESPR (266M). ORGO has higher revenues than ESPR: ORGO (433M) vs ESPR (116M).
ESPRORGOESPR / ORGO
Capitalization496M375M132%
EBITDA-150.11M36M-417%
Gain YTD-46.81832.812-143%
P/E RatioN/A70.25-
Revenue116M433M27%
Total Cash82.2M104M79%
Total Debt266M119M224%
FUNDAMENTALS RATINGS
ESPR vs ORGO: Fundamental Ratings
ESPR
ORGO
OUTLOOK RATING
1..100
7947
VALUATION
overvalued / fair valued / undervalued
1..100
36
Fair valued
72
Overvalued
PROFIT vs RISK RATING
1..100
10099
SMR RATING
1..100
10092
PRICE GROWTH RATING
1..100
6437
P/E GROWTH RATING
1..100
10011
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ESPR's Valuation (36) in the Biotechnology industry is somewhat better than the same rating for ORGO (72) in the Financial Conglomerates industry. This means that ESPR’s stock grew somewhat faster than ORGO’s over the last 12 months.

ORGO's Profit vs Risk Rating (99) in the Financial Conglomerates industry is in the same range as ESPR (100) in the Biotechnology industry. This means that ORGO’s stock grew similarly to ESPR’s over the last 12 months.

ORGO's SMR Rating (92) in the Financial Conglomerates industry is in the same range as ESPR (100) in the Biotechnology industry. This means that ORGO’s stock grew similarly to ESPR’s over the last 12 months.

ORGO's Price Growth Rating (37) in the Financial Conglomerates industry is in the same range as ESPR (64) in the Biotechnology industry. This means that ORGO’s stock grew similarly to ESPR’s over the last 12 months.

ORGO's P/E Growth Rating (11) in the Financial Conglomerates industry is significantly better than the same rating for ESPR (100) in the Biotechnology industry. This means that ORGO’s stock grew significantly faster than ESPR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ESPRORGO
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
86%
Bearish Trend 3 days ago
87%
Momentum
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
80%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
78%
Advances
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
78%
Declines
ODDS (%)
Bearish Trend 6 days ago
90%
Bearish Trend 23 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
84%
Aroon
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 3 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
ESPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORGO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CGACX11.470.13
+1.15%
Calvert Global Energy Solutions C
FUGAX46.190.50
+1.09%
Fidelity Advisor Utilities A
ANOIX22.330.22
+1.00%
American Century Small Cap Growth Inv
IUAAX43.380.19
+0.44%
VY® Invesco Equity and Income A
LYRWX14.410.02
+0.14%
Lyrical International Value Equity Instl

ESPR and

Correlation & Price change

A.I.dvisor indicates that over the last year, ESPR has been loosely correlated with ALKS. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if ESPR jumps, then ALKS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ESPR
1D Price
Change %
ESPR100%
+1.74%
ALKS - ESPR
37%
Loosely correlated
-0.52%
DVAX - ESPR
35%
Loosely correlated
+1.08%
AQST - ESPR
30%
Poorly correlated
+1.09%
AMPH - ESPR
27%
Poorly correlated
-1.61%
AMRX - ESPR
26%
Poorly correlated
+0.60%
More

ORGO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ORGO has been loosely correlated with ANIP. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if ORGO jumps, then ANIP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ORGO
1D Price
Change %
ORGO100%
+4.94%
ANIP - ORGO
49%
Loosely correlated
+0.09%
PRGO - ORGO
47%
Loosely correlated
-0.22%
AMRX - ORGO
32%
Poorly correlated
+0.60%
ACET - ORGO
29%
Poorly correlated
-1.14%
AMPH - ORGO
27%
Poorly correlated
-1.61%
More